Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 6Fallopian Tube Neoplasms 6Breast Neoplasms 6Gliosarcoma 5Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 4Ovarian Neoplasms 4Melanoma 4Carcinoma, Renal Cell 4Brain Neoplasms 4Solitary Fibrous Tumor, Pleural 3Mesothelioma, Malignant 3Carcinoma, Hepatocellular 3Breast Neoplasms, Male 3Triple Negative Breast Neoplasms 2Sarcoma, Alveolar Soft Part 2Rectal Neoplasms 2Oligodendroglioma 2Leukemia, Myeloid, Acute 2Colonic Neoplasms 2Carcinoma, Ovarian Epithelial 2Astrocytoma 2Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Uterine Cervical Neoplasms 1Tongue Neoplasms 1Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Spinal Cord Neoplasms 1

Interventions

atezolizumab 2Specimen Handling 2Magnetic Resonance Spectroscopy 2talazoparib 1olaparib 1cediranib 1Radiotherapy 1Radiation 1Platinum 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Extensive Stage Lung Small Cell Carcinoma × cediranib × Clear all
NCT02899728 2023-10-17

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
9 enrolled 4 charts

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡